Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Heidi D. Finnes
The Impact of Dose Modification and Temporary Interruption of Ibrutinib on Outcomes of Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
Related publications
Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib
Cancer
Cancer Research
Oncology
Beyond Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Cancer therapy & Oncology International Journal
Autoimmune Cytopenias in Patients With Chronic Lymphocytic Leukaemia Treated With Ibrutinib in Routine Clinical Practice at an Academic Medical Centre
British Journal of Haematology
Hematology
Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab Into Clinical Practice
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia With Ibrutinib
Clinical Cancer Research
Cancer Research
Oncology
Persistent Janus Kinase-Signaling in Chronic Lymphocytic Leukemia Patients on Ibrutinib: Results of a Phase I Trial
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
Experience With Ibrutinib in Patients With Refractory and Recurrent B-Cell Chronic Lymphocytic Leukemia
Medical Council
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
